Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGTEPO for Anemia in ESRD Patients on Peritoneal Dialysis
NCT02378662Phase 2Terminated
- Sponsor
- Avalo Therapeutics
- Start
- Apr 2015
- Primary completion
- Jan 2016
- Countries
- 1
01
Overview
Phase 2, open-label trial of MDGN201 in anemia of chronic kidney disease (2 arms), sponsored by Avalo Therapeutics. Primary endpoint: Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum Erythropoietin (EPO) Levels Above Baseline at 52 weeks. Started Apr 2015; status: terminated.
02
Drugs
MDGN201
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT02378662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378662.